



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

NEW APPLICATION TRANSMITTAL

**Transmitted herewith for filing is the patent application of
Inventor(s): Sundelin, Johan et al.**

For: RECOMBINANT C140 RECEPTOR ITS AGONISTS AND ANTAGONISTS, AND NUCLEIC ACIDS ENCODING THE RECEPTOR

1. Type of Application

This new application is for a(n)

- Original (nonprovisional)
 - Design
 - Plant
 - Divisional.
 - Continuation.
 - Continuation-in-part (C-I-P).

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- deposited with the United States Postal Service in an envelope addressed to the Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TRANSMISSION

- transmitted by facsimile to the Patent and Trademark Office.

as "Express Mail Post Office to Addressee"
Mailing Label No. E1 992152619US

Date: August 19, 2003

Signature
Sean Hunziker

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).

"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. : MPI93-006CP1DV1ACN1DV1M

2. Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)

- The new application being transmitted claims the benefit of prior U.S Application Serial No. 10/127,691 filed April 23, 2002; which is a continuation of U.S. Application Serial No. 08/474,414 filed June 7, 1995; which is a divisional of U.S. Application Serial No.08/390,301 filed January 25, 1995; which is a continuation-in-part of U.S. Application Serial No. 08/097,938 filed July 26, 1993 (issued as U.S. Patent No. 5,629,174).

3. Maintenance of Copendency of Prior Application

A. Extension of time in prior application

B. Conditional Petition for Extension of Time in Prior Application

(complete this item, if previous item not applicable)

A conditional petition for extension of time is being filed in the pending **prior** application.

A copy of the conditional petition filed in the prior application is attached.

4. Abandonment of Prior Application (if applicable)

Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

Notification in Parent Application of This Filing

A notification of this continuation is being filed in the parent application from which this application claims priority under 35 U.S.C. Section 120.

5. Papers Enclosed

Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application

58 Pages of Specification, including

49 Pages of Description

8 Pages of Claims

1 Page of Abstract

16 Sheet of Drawings (Figure(s) 1A-13)

The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. Section 1.84(b).

Formal
 Informal

Practitioner's Docket No. : MPI93-006CP1DV1ACN1M

6. Additional Papers Enclosed

- Information Disclosure Statement (37 C.F.R. Section 1.98) (2 pages)
- Form PTO-1449 (PTO/SB/08A and 08B) (2 pages)
- Citations
- Declaration of Biological Deposit
- 34 pages of paper copy of Sequence Listing (37 CFR Section 1.821-1.823) and 4 pages of Submission of "Sequence Listing," Computer Readable Copy, and/or Amendment Pertaining Thereto for Biotechnology Invention Containing Nucleotide and/or Amino Acid Sequence (37 CFR Section 1.821(f))
- Authorization of Attorney(s) to Accept and Follow Instructions from Representative
- Special Comments
- Other: Preliminary Amendment (9 pages)
Copy of Reference WO 89/01947

7. Declaration or Oath (including power of attorney)

- (10 pages) Copy of the executed Combined Declaration and Power of Attorney documents filed in prior U.S. Application Serial No. 08/390,301, filed January 25, 1995.
- Not Enclosed.

8. Assignment

- Assignment of the invention to Millennium Pharmaceuticals, Inc., a copy of which
 - is enclosed.
 - will follow.

Practitioner's Docket No. : MPI93-006CP1DV1ACN1DV1M

9. Fee Calculation (37 C.F.R. Section 1.16)

A. Regular application

CLAIMS AS FILED					
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a) \$750.00
Total Claims (37 C.F.R. Section 1.16(c))	17	- 20 =	0	\$18.00	\$0.00
Independent Claims (37 C.F.R. Section 1.16(b))	3	- 3 =	0	\$84.00	\$0.00
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))	3	\$280.00			\$280.00

Filing Fee Calculation \$1,030.00

- Amendment canceling extra claims is enclosed.
 Amendment deleting multiple-dependencies is enclosed.
 Fee for extra claims is not being paid at this time.

Practitioner's Docket No. : MPI93-006CP1DV1ACN1M

10. Method of Payment of Fees

- Check in the amount of \$ _____.
 Charge Account No. 501668 in the amount of \$1,030.00
A duplicate of this transmittal is attached.

11. Authorization to Charge Additional Fees

- The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 501668.
- 37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)
 37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims)
 37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)
 37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to Section 1.136(a).
 37 C.F.R. Section 1.17 (application processing fees)
 37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. Section 1.311(b))

12. Instructions as to Overpayment

- Credit Account No. 501668.
 Refund

13. Correspondence Address

Direct all future correspondence to:

Customer Number 30405
OR
Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
75 Sidney Street
Cambridge, MA 02139

August 19, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By


Jean M. Silveri
Registration No. 39,030
75 Sidney Street
Cambridge, MA 02139
Telephone - (617) 679-7336
Facsimile - (617) 551-8820

Statement Where No Further Pages Added

This transmittal ends with this page.